Stockscreener 앱 받기
3.89
0.00%
0.00
시간 외 거래:
3.88
-0.01
-0.26%
Eledon Pharmaceuticals Inc 주식(ELDN)의 최신 뉴스
ELDN Technical Analysis & Stock Price Forecast - Intellectia AI
Eledon to present kidney transplant trial data at conference - Investing.com UK
Eledon to present kidney transplant trial data at conference By Investing.com - Investing.com Nigeria
Eledon to present new Phase 2 data on tegoprubart for kidney transplant rejection at June congress - Pluang
New kidney transplant rejection data from tegoprubart at ATC - Stock Titan
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TradingKey - TradingKey
BVF Group Discloses Convertible Stakes in Eledon (ELDN) — 9.99% Blockers - Stock Titan
ELDN Should I Buy - Intellectia AI
Eledon Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $8.2, Implies 111% Upside - TradingView
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Raises Target Price to $6 - Moomoo
How Should Investors Value Eledon Pharmaceuticals (ELDN) After Q - GuruFocus
Eledon (ELDN) Advances in Tegoprubart Development with Key Miles - GuruFocus
Eledon Pharmaceuticals (ELDN) Reports Q1 Loss, Cash Reserves Dec - GuruFocus
Eledon Pharma Expects Cash, Cash Equivalents and Short-Term Investments to Fund Ops Into 2Q 2027 >ELDN - Moomoo
Eledon Pharmaceuticals 1Q Loss/Shr 33c >ELDN - Moomoo
Eledon Pharmaceuticals reports Q1 EPS (33c), consensus (23c) - TipRanks
Eledon Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eledon Pharmaceuticals Q1 net loss widens on warrant liability loss - TradingView
Eledon Pharmaceuticals (ELDN) deepens Q1 2026 loss as R&D rises but cash totals $111M - Stock Titan
[8-K] Eledon Pharmaceuticals, Inc. Reports Material Event - Stock Titan
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Experimental drug helps 10 transplant patients ditch insulin entirely - Stock Titan
[EFFECT] Eledon Pharmaceuticals, Inc. SEC Filing - Stock Titan
Number of shareholders of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
[S-3] Eledon Pharmaceuticals, Inc. Shelf Registration Statement - Stock Titan
SEC Form DEFA14A filed by Eledon Pharmaceuticals Inc. - Quantisnow
[ARS] Eledon Pharmaceuticals, Inc. SEC Filing - Stock Titan
Major share authorization increase on ballot in Eledon (NASDAQ: ELDN) 2026 proxy - Stock Titan
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 - The Manila Times
NewcelX and Eledon Pharmaceuticals Collaborate on NCEL-101 for Type 1 Diabetes, Reporting Strong Financial Position and Strategic Growth Plans - Quiver Quantitative
NewcelX Reports Financial Results for 2025 and Provides Shareholders With Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration With Eledon Pharmaceuticals in 2026 - 富途牛牛
Eledon Pharmaceuticals (ELDN) Price Target Decreased by 14.93% to 8.33 - MSN
We fact-checked the hype behind the Eledon Pharmaceuticals Type 1 diabetes treatment - Healthcare Brew
BlackRock (NYSE) reports 4.38M-share stake in Eledon (ELDN) - Stock Titan
Eledon Pharmaceuticals drops 10% on stock offering - MSN
ELDN Price Today: Eledon Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Eledon Pharmaceuticals (NASDAQ: ELDN) proposes 450M-share authorization increase - Stock Titan
Eledon Pharmaceuticals (ELDN) Partners with NewcelX to Enhance D - GuruFocus
5 Unstoppable Stocks That Could Double Your Money - Insider Monkey
Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your Money - Insider Monkey
NewcelX Ltd. Enhances Type 1 Diabetes Program with Strategic Collaboration with Eledon Pharmaceuticals - Quiver Quantitative
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference - marketscreener.com
NewcelX heads to Swiss Biotech with a Type 1 diabetes strategy - Stock Titan
We're Not Very Worried About Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Rate - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Down 14.5% in March - MarketBeat
Big Picture: Can Eledon Pharmaceuticals Inc outperform under higher oil pricesWeekly Trade Review & AI Forecast for Swing Trade Picks - baoquankhu1.vn
EPS Watch: Is Eledon Pharmaceuticals Inc backed by strong institutional buyingWeekly Market Outlook & Short-Term Swing Trade Alerts - baoquankhu1.vn
SG Americas Securities LLC Makes New Investment in Eledon Pharmaceuticals, Inc. $ELDN - MarketBeat
0.98%
0.12%
자본화:
|
볼륨(24시간):